Understanding the role of parkin in Parkinson's disease

Singapore General Hospital Proceedings

Volumn 14, Issue 1, 2005, Pages 59-67

  Leong, Lim Kah ^a,b   Tan, Jeanne M M ^a  

^a NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Lewy body; PARK 2; Proteasome; Ubiquitin ligase

Indexed keywords

HALOPERIDOL; METHAMPHETAMINE; PARKIN; UBIQUITIN PROTEIN LIGASE;

BIOGENESIS; CONFERENCE PAPER; DOPAMINERGIC NERVE CELL; FAMILIAL DISEASE; GENE FUNCTION; GENE MUTATION; GENETIC LINKAGE; HUMAN; IDIOPATHIC DISEASE; LEWY BODY; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PHENOTYPE; PROTEIN FUNCTION;

EID: 20344375763     PISSN: 02183048     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (48)

1. Siderowf A, Stern M. Update on Parkinson disease. Ann Intern Med 2003; 138:651-8.
2. Zhang ZX, Roman GC. Worldwide occurrence of Parkinson's disease: an updated review. Neuroepidemiology 1993; 12:195-208.
3. Tan LC, Venketasubramanian N, Hong CY, Sahadevan S, Chin JJ, Krishnamoorthy ES, et al. Prevalence of Parkinson disease in Singapore: Chinese vs Malays vs Indians. Neurology 2004; 62:1999-2004.
4. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 1996; 55:259-72.
5. Dawson TM, Dawson VL. Neuroprotective and neurorestorative strategies for Parkinson's disease. Nat Neurosci 2002; 5 Suppl:1058-61.
6. Zhang Y, Dawson VL, Dawson TM. Oxidative stress and genetics in the pathogenesis of Parkinson's disease. Neurobiol Dis 2000; 7:240-50.
7. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 2003; 53:526-38.
8. Lim KL, Lim TM. Molecular mechanisms of neurodegeneration in Parkinson's disease: clues from Mendelian syndromes. IUBMB Life 2003; 55:315-22.
9. Lim KL, Dawson VL, Dawson TM. The genetics of Parkinson's disease. Curr Neurol Neurosci Rep 2002; 2:439-46.
10. Valente EM, Sleiman PM, Caputo V, Muqit MMK, Harvey K, Gispert S. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004; 304:1158-60.
11. Zhang Y, Gao J, Chung KK, Huang H, Dawson VL, Dawson TM. Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc Natl Acad Sci USA 2000; 97:13354-9.
12. Imai Y, Soda M, Takahashi R. Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J Biol Chem 2000; 275:35661-4.
13. Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 2000; 25:302-5.
14. Lucking CB, Durr A, Bonifati V, Vaughan J, De Michele G, Gasser T, et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. French Parkinson's Disease Genetics Study Group. N Engl J Med 2000; 342:1560-7.
15. Mata IF, Lockhart PJ, Farrer MJ. Parkin genetics: one model for Parkinson's disease. Hum Mol Genet 2004; 13 Spec No 1:R127-33.
16. West A, Periquet M, Lincoln S, Lucking CB, Nicholl D, Bonifati V, et al. Complex relationship between Parkin mutations and Parkinson disease. Am J Med Genet 2002; 114:584-91.
17. Feany MB, Pallanck LJ. Parkin. A multipurpose neuroprotective agent? Neuron 2003; 38:13-6.
18. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392:605-8.
19. Foroud T, Uniacke SK, Liu L, Pankratz N, Rudolph A, Halter C, et al. Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease. Neurology 2003; 60:796-801.
20. Hilker R, Klein C, Ghaemi M, Kis B, Strotmann T, Ozelius LJ, et al. Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene. Ann Neurol 2001; 49:367-76.
21. West AB, Maraganore D, Crook J, Lesnick T, Lockhart PJ, Wilkes KM, et al. Functional association of the parkin gene promoter with idiopathic Parkinson's disease. Hum Mol Genet 2002; 11:2787-92.
22. West A, Farrer M, Petrucelli L, Cookson M, Lockhart P, Hardy J. Identification and characterization of the human parkin gene promoter. J Neurochem 2001; 78:1146-52.
23. Asakawa S, Tsunematsu K, Takayanagi A, Sasaki T, Shimizu A, Shintani A, et al. The genomic structure and promoter region of the human parkin gene. Biochem Biophys Res Commun 2001; 286:863-8.
24. West AB, Lockhart PJ, O'Farell C, Farrer MJ. Identification of a novel gene linked to parkin via a bi-directional promoter. J Mol Biol 2003; 326:11-9.
25. Nakahara T, Gotoh L, Motomura K, Kawanami N, Ohta E, Hirano M, et al. Acute and chronic haloperidol treatments increase parkin mRNA levels in the rat brain. Neurosci Lett 2001; 306:93-6.
26. Nakahara T, Kuroki T, Ohta E, Kajihata T, Yamada H, Yamanaka M, et al. Effect of the neurotoxic dose of methamphetamine on gene expression of parkin and Pael-receptors in rat striatum. Parkinsonism Relat Disord 2003; 9:213-9.
27. Yu WP, Tan MM, Chew CMK, Oh T, Kolatkar P, Venkatesh B, et al. The 350-fold compacted Fugu parkin gene is structurally and functionally similar to human Parkin. Gene in press.
28. Pickart CM. Mechanisms underlying ubiquitination. Annu Rev Biochem 2001; 70:503-33.
29. Chung KK, Zhang Y, Lim KL, Tanaka Y, Huang H, Gao J, et al. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat Med 2001; 7:1144-50.
30. Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, Schneider R, et al. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 2001; 293:263-9.
31. Imai Y, Soda M, Inoue H, Hattori N, Mizuno Y, Takahashi R. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell 2001; 105:891-902.
32. Choi P, Snyder H, Petrucelli L, Theisler C, Chong M, Zhang Y, et al. SEPT5_v2 is a parkin-binding protein. Brain Res Mol Brain Res 2003; 117:179-89.
33. Cookson MR. Neurodegeneration: how does parkin prevent Parkinson's disease? Curr Biol 2003; 13:R522-4.
34. Tsai YC, Fishman PS, Thakor NV, Oyler GA. Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function. J Biol Chem 2003; 278:22044-55.
35. Liani E, Eyal A, Avraham E, Shemer R, Szargel R, Berg D, et al. Ubiquitylation of synphilin-1 and alpha-synuclein by SIAH and its presence in cellular inclusions and Lewy bodies imply a role in Parkinson's disease. Proc Natl Acad Sci USA 2004; 101:5500-5.
36. Ito T, Niwa J, Hishikawa N, Ishigaki S, Doyu M, Sobue G. Dorfin localizes to Lewy bodies and ubiquitylates synphilin-1. J Biol Chem 2003; 278:29106-14.
37. Petrucelli L, O'Farrell C, Lockhart PJ, Baptista M, Kehoe K, Vink L, et al. Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 2002; 36:1007-19.
38. Kim SJ, Sung JY, UmJW, Hattori N, Mizuno Y, Tanaka K, et al. Parkin cleaves intracellular alpha-synuclein inclusions via the activation of calpain. J Biol Chem 2003; 278:41890-9.
39. Ardley HC, Scott GB, Rose SA, Tan NG, Markham AF, Robinson PA. Inhibition of proteasomal activity causes inclusion formation in neuronal and non-neuronal cells overexpressing Parkin. Mol Biol Cell 2003; 14:4541-56.
40. McNaught KS, Bjorklund LM, Belizaire R, Isacson O, Jenner P, Olanow CW. Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport 2002; 13:1437-41.
41. McNaught KS, Belizaire R, Isacson O, Jenner P, Olanow CW. Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol 2003; 179:38-46.
42. Pawlyk AC, Giasson BI, Sampathu DM, Perez FA, Lim KL, Dawson YL, et al. Novel monoclonal antibodies demonstrate biochemical variation of brain parkin with age. J Biol Chem 2003; 278:48120-8.
43. Itier JM, Ibanez P, Mena MA, Abbas N, Cohen-Salmon C, Bohme GA, et al. Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum Mol Genet 2003; 12:2277-91.
44. Goldberg MS, Fleming SM, Palacino JJ, Cepeda C, Lam HA, Bhatnagar A, et al. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem 2003; 278:43628-35.
45. Von Coelln R, Thomas B, Savitt JM, Lim KL, Sasaki M, Hess EJ, et al. Loss of locus coeruleus neurons and reduced startle in parkin null mice. Proc Natl Acad Sci USA 2004; 101:10744-9.
46. Sunada Y, Saito F, Matsumura K, Shimizu T. Differential expression of the parkin gene in the human brain and peripheral leukocytes. Neurosci Lett 1998; 254:180-2.
47. Huang PL, Dawson TM, Bredt DS, Snyder SH, Fishman MC. Targeted disruption of the neuronal nitric oxide synthase gene. Cell 1993; 75:1273-86.
48. Zhang Y, Dawson VL, Dawson TM. Parkin: Clinical aspects and neurobiology. Clinical Neuroscience Research 2001; 1:467-82.